Harnessing the power of precision medicine to conquer Alzheimer’s disease.

Latest Company News

Recent Posts / View All Posts

ProMIS Biotech Hopes to Prove Amyloid Theory in Alzheimer’s with New Targeted Therapies

| News | No Comments

From Alzheimer’s News Today DECEMBER 2, 2016 BY MAGDALENA KEGEL In the wake of the failure of the investigational drug solanezumab, which stirred the debate over whether the prevailing amyloid theory of Alzheimer’s disease is still a viable working hypothesis, ProMIS…

ProMIS Neurosciences announces five novel Alzheimer’s disease therapeutic candidates block spreading of toxic prion-like forms of Amyloid beta

| News | No Comments

ProMIS Neurosciences, Inc. NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE ProMIS Neurosciences announces five novel Alzheimer’s disease therapeutic candidates block spreading of toxic prion-like forms of Amyloid beta TORONTO, Ontario – November 30, 2016 – ProMIS Neurosciences (“ProMIS” or the “Company”), a…

Latest Company Commentary

Recent Posts / View All Posts

Results of Lilly’s Solanezumab trial confirm the “real” beta-Amyloid hypothesis

| Commentary | No Comments

Please view our latest corporate commentary from November 28th, 2016 “Results of Lilly’s Solanezumab trial confirm the “real” beta-Amyloid hypothesis” (PDF)

Critical Insight: Toxic soluble Amyloid beta oligomers (“prions”), not plaque, drive pathogenesis in Alzheimer’s disease

| Commentary | No Comments

Critical Insight:  Toxic soluble Amyloid beta oligomers (“prions”), not plaque, drive pathogenesis in Alzheimer’s disease Refinement of the Amyloid beta cascade hypothesis – Prions vs. Plaque The presence of Amyloid beta (Aβ) plaque is a hallmark of Alzheimer’s disease (AD)…

Latest Company Presentations

Traded on the Toronto Stock Exchange (TSX), under the symbol PMN


ProMIS™ Neurosciences, Inc., is a development stage biotech company that discovers and develops game changing precision therapeutics for treatment of neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS).

Product Portfolio

Investors

News

Management Team

Eugene Williams

Eugene Williams

Executive Chairman

Eugene Williams is a former SVP at Genzyme, with senior roles integrating commercialization, drug development, and deal making. He is also an entrepreneur, as the founder and director of Adheris, which became the largest company in the patient adherence area. He was previously a strategy consultant at Bain and Corporate Decisions Inc. (a Bain Spin off, now part of Oliver Wyman), where he was co-Head of Healthcare and spent extensive time on speeding and improving the drug development process and on commercialization strategies. Mr. Williams was most recently the CEO of Dart Therapeutics, an Orphan Disease drug development company. Mr. Williams holds a B.A. from Harvard University and an M.B.A. from Harvard Business School.

Dr. Elliot Goldstein

Dr. Elliot Goldstein

President and CEO

Elliot Goldstein brings a unique track record in the clinical, regulatory and commercial development of new pharmaceuticals. Dr. Goldstein began his career with Sandoz Pharmaceuticals (now Novartis), a fourteen-year period on drug development in France, Basel, Switzerland Global Headquarters, including as Head of Clinical R&D in the United States. He subsequently held positions as SVP of Strategic Product Development at SmithKline Beecham (now GSK), CEO of British Biotech (Oxford, UK), Chief Operating Officer and Chief Medical Officer of Maxygen, and President and CMO of a startup biotech devoted to development of biosimilar monoclonal antibodies. Dr. Goldstein holds an M.D. from the University Aix-Marseille II, Marseille, France, and a B.Sc. from McGill University, Montreal.

Dr. Neil Cashman

Dr. Neil Cashman

Chief Scientific Officer and Co-founder

Dr. Cashman is a physician and scientist focused on neurodegenerative diseases. His first academic posting was at Montreal Neurological Institute and Hospital of McGill University. From 1998 to 2005, he was the Diener Professor of Neurodegenerative Diseases at the University of Toronto. In 2005, Professor Cashman moved to the University of British Columbia, where he holds the Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases, and serves as the Director of the UBC ALS Centre. He has procured over $50 million in research grant funding from the CIHR, CRC, NCE, NIH, and various corporations for his work involving protein misfolding and prion technologies. He was awarded the Jonas Salk Prize for biomedical research in 2000, and was elected a Fellow of the Canadian Academy of Health Sciences in 2008. He is recognized worldwide as one of the leading research scientists pioneering the emerging fields of prion biology and protein misfolding diseases, in particular Alzheimer’s disease and amyotrophic lateral sclerosis (ALS).

Steven Plotkin, Ph.D

Steven Plotkin, Ph.D

Chief Physics Officer

Prof. Steven Plotkin is a theoretical and computational biophysicist whose research focuses on protein folding and misfolding in neurodegenerative disease, protein evolution and cellular differentiation, and the molecular mechanisms of cancer. He has been a professor at UBC in the Department of Physics and Astronomy since 2001, where he was appointed as the Canada Research Chair in Theoretical Molecular Biophysics. He was an Alfred P. Sloan Research Fellow in 2005-2006, a Killam Faculty Research Fellow in 2010, and is now an associate member of the Genome Sciences and Technology Program, the Bioinformatics Program, and the Institute for Applied Mathematics at the University of British Columbia. Several of his publications have received the Faculty of 1000 designation, placing them in the top 2% of published articles in biology and medicine.
Plotkin is recognized internationally for his fundamental contributions to the energy landscape theory of protein folding, and presents his research findings in protein misfolding and neurodegeneration, and protein geometry and disorder as an invited speaker at several annual conferences and symposia. His research is currently supported by grants from CIHR, NSERC, APRI, ALS-Canada, and Compute Canada.

Johanne Kaplan, PhD

Johanne Kaplan, PhD

Chief Development Officer

Johanne Kaplan is a former VP of Research at Genzyme, a Sanofi Company. Over the course of her 24-year career at Genzyme, Dr. Kaplan directed pioneering research leading to the implementation of multiple clinical trials in the fields of gene therapy, cancer immunotherapy and autoimmunity. Most recently, as VP of Neuroimmunology Research, Dr. Kaplan led the contribution of the Genzyme science team supporting the approval of Lemtrada (alemtuzumab) and Aubagio (teriflunomide) for the treatment of relapsing-remitting multiple sclerosis. She also established partnerships for the development of novel therapies for neuroinflammatory disorders. Prior to joining Genzyme, Dr. Kaplan was an Associate Immunopathologist at SmithKline Beecham where she established an Immunotoxicology program. Her work has resulted in over 60 scientific publications and multiple patents. Dr. Kaplan holds a Ph.D. in Microbiology & Immunology from McGill University in Montreal, Canada and conducted post-doctoral studies at the Albert Einstein College of Medicine in New York, USA.

Janet Clennett

Janet Clennett

Director of Finance and Acting CFO

Janet Clennett is a Chartered Professional Accountant (CPA, CA) who has held several senior financial management positions in emerging biotechnology firms. Ms. Clennett first joined the Company as Director of Finance in November of 2007. During her 7 year tenure she held the positions of Acting CFO, and subsequently CFO from September 2010 to January 2013. Prior to that, she worked as Controller, then CFO of Fralex Therapeutics Inc. (2005-2007) and as Controller of Novadaq Technologies Inc. (2002-2005). Janet earned her CPA, CA while employed at KPMG. Ms. Clennett has an Honours Bachelor of Mathematics degree from the University of Waterloo.

Precision Medicine


Targeting the right drug to the right patient by using both a diagnostic and a therapeutic together – has had dramatic positive impact in a number of diseases. It appears to be important in Alzheimer’s and neurodegenerative disease as well.

As its primary objective, the Company will focus on the discovery and development of precision therapeutics directed against several strains of misfolded, neurotoxic prion forms of Amyloid beta (Aβ), the root cause of Alzheimer’s.